Expanding the investigation to include the China allegations is a routine step.
U.K. laws could prevent it from pursuing a case against one of its own companies if Chinese and U.S. authorities have gotten there first.
A probe of JPMorgan Chase & Co.’s hiring practices in China has uncovered red flags across Asia, including an internal spreadsheet that linked appointments to specific deals pursued by the bank, people with knowledge of the matter said.
U.S. drugmaker Eli Lilly and Co said it was “deeply concerned” about allegations published in a Chinese newspaper that it spent more than 30 million yuan ($4.90 million) to bribe doctors in China to prescribe the firm’s medicines instead of rival products.
The U.S. has taken the lead on investigating the mining concern, with Australian authorities embarrassed into taking belated action.
Chinese authorities have recently brought intense pressure to bear on foreign drug makers over alleged bribery.
Company directors won plaudits for the acquisition of a Chinese drug maker in 2011 but the outcome has been less rosy than it may originally have seemed.
At the moment, then, there are (at least) four investigations by Chinese authorities into foreign companies: Baxter, Sanofi, GSK and AstraZeneca.
A low-ball initial offer is rejected and Avon says it expects to pay more for alleged bribes in China and other countries. (Subscription required)
Just Anti-Corruption reported the disclosure as it occurred last year. Other media suggested the disclosure was made this week.
The judge refused to approve the deal for two years without the company agreeing to file reports to both him and the SEC on any potential violation.
If GSK isn’t the only pharmaceutical company under investigation by Chinese authorities, a look to the list of drug makers whose conduct in China has also been probed by the United States may offer clues to the others.
Chinese authorities have detained four GSK executives on bribery allegations in a notably aggressive crackdown on the British pharmaceutical company.
U.K. drug maker GlaxoSmithKline PLC is investigating allegations that sales personnel in China rewarded doctors with cash and perks for prescribing Botox, and allegedly tried to cover their tracks by using private email, as part of a broader probe into allegations of bribery that date back several years.
Drug manufacturer GlaxoSmithKline said Thursday it has investigated an accusation that its salespeople in China bribed doctors and found no evidence of wrongdoing.
President Obama announces Loretta Lynch as nominee for Attorney General.